IL138677A0 - Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists - Google Patents
Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonistsInfo
- Publication number
- IL138677A0 IL138677A0 IL13867799A IL13867799A IL138677A0 IL 138677 A0 IL138677 A0 IL 138677A0 IL 13867799 A IL13867799 A IL 13867799A IL 13867799 A IL13867799 A IL 13867799A IL 138677 A0 IL138677 A0 IL 138677A0
- Authority
- IL
- Israel
- Prior art keywords
- glycyl
- heterocyclic
- beta
- alanine derivatives
- vitronectin antagonists
- Prior art date
Links
- -1 Heterocyclic glycyl beta-alanine derivatives Chemical class 0.000 title 1
- 102100035140 Vitronectin Human genes 0.000 title 1
- 108010031318 Vitronectin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8139498P | 1998-04-10 | 1998-04-10 | |
| PCT/US1999/004297 WO1999052896A1 (en) | 1998-04-10 | 1999-04-09 | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL138677A0 true IL138677A0 (en) | 2001-10-31 |
Family
ID=22163868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13867799A IL138677A0 (en) | 1998-04-10 | 1999-04-09 | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1070060A1 (cs) |
| JP (1) | JP2002511462A (cs) |
| KR (1) | KR20010042614A (cs) |
| CN (1) | CN1304406A (cs) |
| AR (1) | AR015759A1 (cs) |
| AU (1) | AU765294B2 (cs) |
| BR (1) | BR9910119A (cs) |
| CA (1) | CA2326665A1 (cs) |
| CZ (1) | CZ20003672A3 (cs) |
| IL (1) | IL138677A0 (cs) |
| MY (1) | MY133473A (cs) |
| NO (1) | NO20005084L (cs) |
| NZ (1) | NZ507292A (cs) |
| PL (1) | PL343406A1 (cs) |
| RU (1) | RU2215746C2 (cs) |
| TW (1) | TWI247008B (cs) |
| WO (1) | WO1999052896A1 (cs) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| BR9916536A (pt) * | 1998-12-23 | 2002-01-02 | Searle & Co | Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação |
| US6297233B1 (en) | 1999-02-09 | 2001-10-02 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| NZ514602A (en) | 1999-04-12 | 2003-06-30 | Aventis Pharma Ltd | Substituted bicyclic heteroaryl compounds as integrin antagonists |
| MXPA01010834A (es) * | 1999-04-28 | 2002-04-24 | Basf Ag | Antagonistas de los receptores para integrina. |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6720315B2 (en) | 2000-06-15 | 2004-04-13 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives |
| AU2001275724A1 (en) | 2000-08-02 | 2002-02-13 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| JP2006514050A (ja) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体 |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP2386558B1 (de) | 2007-10-18 | 2014-10-01 | Boehringer Ingelheim International GmbH | CGRP-Antagonisten |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| WO2009065922A2 (de) * | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| WO2009065919A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| EP2875021B1 (en) | 2012-07-18 | 2017-08-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
| KR20180107121A (ko) | 2015-12-30 | 2018-10-01 | 세인트 루이스 유니버시티 | 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체 |
| CN110139864B (zh) * | 2016-11-08 | 2022-08-23 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的吡咯酰胺 |
| EP4151632A4 (en) * | 2020-05-14 | 2024-04-24 | UBE Corporation | 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| JPWO2023085396A1 (cs) * | 2021-11-12 | 2023-05-19 | ||
| CN115626912B (zh) * | 2022-09-27 | 2024-03-26 | 中山大学 | 一种硫脲化合物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| RU2126001C1 (ru) * | 1995-01-10 | 1999-02-10 | Самдзин Фармасьютикал Ко., Лтд | Производные пиперазина и фармацевтическая композиция на их основе |
| BR9610422A (pt) * | 1995-08-30 | 1999-07-13 | Searle & Co | Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| CA2263999A1 (en) * | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
-
1999
- 1999-04-09 CZ CZ20003672A patent/CZ20003672A3/cs unknown
- 1999-04-09 NZ NZ507292A patent/NZ507292A/en unknown
- 1999-04-09 AR ARP990101636A patent/AR015759A1/es unknown
- 1999-04-09 EP EP99916119A patent/EP1070060A1/en not_active Withdrawn
- 1999-04-09 TW TW088105718A patent/TWI247008B/zh active
- 1999-04-09 CN CN99807091A patent/CN1304406A/zh active Pending
- 1999-04-09 RU RU2000128033/04A patent/RU2215746C2/ru not_active IP Right Cessation
- 1999-04-09 CA CA002326665A patent/CA2326665A1/en not_active Abandoned
- 1999-04-09 WO PCT/US1999/004297 patent/WO1999052896A1/en not_active Application Discontinuation
- 1999-04-09 IL IL13867799A patent/IL138677A0/xx unknown
- 1999-04-09 KR KR1020007011291A patent/KR20010042614A/ko not_active Ceased
- 1999-04-09 JP JP2000543454A patent/JP2002511462A/ja active Pending
- 1999-04-09 PL PL99343406A patent/PL343406A1/xx unknown
- 1999-04-09 BR BR9910119-0A patent/BR9910119A/pt not_active IP Right Cessation
- 1999-04-09 AU AU34499/99A patent/AU765294B2/en not_active Ceased
- 1999-04-10 MY MYPI99001398A patent/MY133473A/en unknown
-
2000
- 2000-10-09 NO NO20005084A patent/NO20005084L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3449999A (en) | 1999-11-01 |
| BR9910119A (pt) | 2001-10-09 |
| RU2215746C2 (ru) | 2003-11-10 |
| CA2326665A1 (en) | 1999-10-21 |
| NO20005084D0 (no) | 2000-10-09 |
| NO20005084L (no) | 2000-11-27 |
| PL343406A1 (en) | 2001-08-13 |
| WO1999052896A1 (en) | 1999-10-21 |
| TWI247008B (en) | 2006-01-11 |
| AR015759A1 (es) | 2001-05-16 |
| KR20010042614A (ko) | 2001-05-25 |
| CZ20003672A3 (cs) | 2001-08-15 |
| NZ507292A (en) | 2003-12-19 |
| EP1070060A1 (en) | 2001-01-24 |
| JP2002511462A (ja) | 2002-04-16 |
| AU765294B2 (en) | 2003-09-11 |
| CN1304406A (zh) | 2001-07-18 |
| MY133473A (en) | 2007-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL343406A1 (en) | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists | |
| PL350451A1 (en) | Amide derivatives | |
| HUP0202450A3 (en) | N-heterocyclic derivatives as nos inhibitors | |
| GB9929973D0 (en) | Heterocyclic compounds | |
| IL141445A0 (en) | Benzazine derivatives as phosphodiesterase 4 inhibitors | |
| IL145741A0 (en) | Piperazine derivatives useful as ccrs antagonists | |
| IL144577A0 (en) | Peptidyl heterocyclic ketones useful as tryptase inhibitors | |
| IL148058A0 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
| PL352296A1 (en) | Crystalline derivatives of 1-methylocarbapeneme | |
| DK1153014T3 (da) | Beta-alaninderivater | |
| IL148623A0 (en) | Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists | |
| IL150357A0 (en) | Substituted piperazine derivatives as mtp inhibitors | |
| GB0026578D0 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| AP2002002413A0 (en) | Heterocyclic compounds inhibiting angiogenesi | |
| PL352409A1 (en) | Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane | |
| IL150862A0 (en) | Heterocyclic amide derivatives | |
| IL150010A0 (en) | Heterocyclic derivatives | |
| IL141602A0 (en) | Bridged heterocyclic derivatives | |
| GB0027548D0 (en) | Bicyclic amide derivatives | |
| GB9903337D0 (en) | Heterocyclic derivatives | |
| GB9929038D0 (en) | Heterocyclic derivatives | |
| SI1198453T1 (en) | N-(indolcarbonyl-)piperazin derivatives | |
| GB9912782D0 (en) | Pyrimidine derivatives | |
| GB9812410D0 (en) | Heterocyclic derivatives | |
| GB9809351D0 (en) | Heterocyclic derivatives |